Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL1643487 | 1.00 | CA4 (0.52) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL28000818 | 1.00 | CA4 (0.52) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL27610616 | 1.00 | CA4 (0.52) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL8512435 | 0.97 | CA4 (0.47) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL7911623 | 0.91 | CA4 (0.42) | CA4LMNAPDE4A | |
| Citric Acid SCHEMBL21807344 | 0.89 | CA4 (0.65) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL21807340 | 0.89 | CA4 (0.65) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL25267224 | 0.87 | CA4 (0.61) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL60075 | 0.87 | CA4 (0.61) | CA4LMNAPDE4AL3MBTL1TDP1 | |
| Citric Acid SCHEMBL30809599 | 0.82 | CA4 (0.59) | CA4LMNAPDE4AL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115259207-A | Preparation method of tetradecahedron cuprous oxide | 西北工业大学 | 2022-11-01 | — | — | CN | claimed |
| WO-2020205299-A1 | DETECTING CANCER BIOMARKER PROTEINS IN BLOOD | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-10-08 | — | — | WO | claimed |
| CN-115259207-B | Preparation method of fourteen-surface cuprous oxide | 西北工业大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-113621026-B | Polypeptide and application thereof in preparation of medicines for treating thrombocytosis or resisting tumor metastasis | 苏州大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20230079113-A1 | Biomaterial for Articular Cartilage Maintenance and Treatment of Arthritis | RHODE ISLAND HOSPITAL | 2023-03-16 | — | — | US | disclosed |
| CN-115259207-A | Preparation method of tetradecahedron cuprous oxide | 西北工业大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-115068597-A | Treatment of cancer using recall antigens delivered by attenuated bacteria | 阿尔伯特爱因斯坦医学院 | 2022-09-20 | — | — | CN | disclosed |
| CN-107708713-B | Treatment of cancer using recall antigens delivered by attenuated bacteria | 阿尔伯特爱因斯坦医学院公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-2809340-B1 | BIOMATERIAL FOR ARTICULAR CARTILAGE MAINTENANCE AND TREATMENT OF ARTHRITIS | CHILDRENS MEDICAL CENTER (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-111934043-B | Recovery process of waste lead-acid storage battery lead plaster | 湖南省长城新能源科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-113330034-A | Monoclonal antibodies directed against the IgV domain of B7-H3 and uses thereof | 阿尔伯特爱因斯坦医学院 | 2021-08-31 | — | — | CN | disclosed |
| CN-103987401-A | MFG-E8 AND USES THEREOF | THE FEINSTEIN INST MEDICAL RES | 2014-08-13 | — | — | CN | disclosed |
| WO-2013116744-A1 | BIOMATERIAL FOR ARTICULAR CARTILAGE MAINTENANCE AND TREATMENT OF ARTHRITIS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-2619356-A2 | PREPARATION RICH IN GROWTH FACTOR-BASED FIBROUS MATRICES FOR TISSUE ENGINEERING, GROWTH FACTOR DELIVERY, AND WOUND HEALING | Virginia Commonwealth University (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130177623-A1 | Preparation Rich in Growth Factor-Based Fibrous Matrices for Tissue Engeering, Growth Factor Delivery, and Wound Healling | VIRGINIA COMMONWEALTH UNIVERSITY | 2013-07-11 | — | — | US | disclosed |
| EP-2490721-A1 | COMPOSITIONS, METHODS FOR TREATMENT, AND DIAGNOSES OF AUTOIMMUNITY-RELATED DISORDERS AND METHODS FOR MAKING SUCH COMPOSITIONS | Eiger Health Partners, LLC (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012040310-A2 | PREPARATION RICH IN GROWTH FACTOR-BASED FIBROUS MATRICES FOR TISSUE ENGINEERING, GROWTH FACTOR DELIVERY, AND WOUND HEALING | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110097344-A1 | Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions | EIGER HEALTH PARTNERS, LLC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011050259-A1 | COMPOSITIONS, METHODS FOR TREATMENT, AND DIAGNOSES OF AUTOIMMUNITY-RELATED DISORDERS AND METHODS FOR MAKING SUCH COMPOSITIONS | EIGER HEALTH PARTNERS, LLC (US) | 2011-04-28 | — | — | WO | disclosed |
| CN-1823870-A | Celastrus orbiculatus ready prepared Chinese medicine and its application in resisting rheumatoid disease | UNIV NANFANG MEDICAL (CN) | 2006-08-30 | — | — | CN | disclosed |